Newcourt Acquisition Corp: directors' dealings · United States · SEC (Form 4)

About Newcourt Acquisition Corp

Newcourt Acquisition Corp is a US-listed SPAC traded on the NASDAQ in the United States. It was incorporated on February 25, 2021 in the Cayman Islands, and was formed not to run a traditional operating business, but to pursue a merger, share exchange, asset acquisition, recapitalization, reorganization, or similar business combination with one or more private companies. For investors, that means the equity story is fundamentally event-driven: the company’s value is tied to deal execution, target quality, and the eventual economics of any announced combination. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1849475/000110465921122965/tm219717-16_s1a.htm?utm_source=openai)) From an analytical standpoint, Newcourt’s business model is that of a capital-markets vehicle rather than a product company. SEC filings describe the company as a blank-check entity with no initial restriction to a specific industry or geographic region, which gave management broad discretion in target selection. Recent SEC materials also identify an Oakland, California address, which provides the operating base in the United States even though the issuer’s original formation jurisdiction was the Cayman Islands. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1849475/000141057823002572/ncacu-20230930x10q.htm?utm_source=openai)) Because Newcourt is a SPAC, it does not have conventional operating segments such as manufacturing, distribution, or recurring service lines. Its “core product” is access to public markets through a business combination. The competitive positioning therefore depends on sponsor credibility, the attractiveness of the target, the structure of the merger, and the ability to satisfy closing conditions. In a crowded SPAC landscape, the key differentiators are often transaction discipline, financing certainty, and the market’s willingness to accept the combined company’s long-term growth profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1849475/000141057823002572/ncacu-20230930x10q.htm?utm_source=openai)) The most important recent development is the announced business combination with Psyence Group Inc. and Psyence Biomed, a biotechnology company focused on natural psilocybin-based solutions for mental health and palliative care. Newcourt announced the definitive agreement on January 9, 2023, and later SEC-related updates in 2024 indicated that closing conditions had not yet been satisfied at that time. That effectively shifts the investment narrative toward Health & Pharma, because the post-transaction equity case is expected to be driven by a life-science platform rather than by Newcourt’s original SPAC structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1849475/000110465923002364/tm232749d2_ex99-1.htm?utm_source=openai))